CPA
RDHL

Capital Performance Advisors’s Redhill Biopharma RDHL Stock Holding History

Capital Performance Advisors’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$44 – 2090
2024
Q3 		$44 Buy
+5
New +$49 ﹤0.01% 2802

Other funds holding RDHL

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
VWM
Vermillion Wealth Management Rosemount, Minnesota $427M AUM 12.63% 1-Year Est. Return

Capital Performance Advisors's RDHL Position: Q4 2024 in Review

Capital Performance Advisors sold out of Redhill Biopharma (RDHL) in Q4 2024, closing a stake of 5 shares — an estimated $44 sold.

Capital Performance Advisors first reported a position in RDHL in Q3 2024 and held it in 1 quarter. The position peaked at $44 in Q3 2024. 11 funds tracked by Wall St. Rank hold RDHL as of Q4 2024.

  • Capital Performance Advisors reported no remaining Redhill Biopharma position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 5 Redhill Biopharma shares in Q4 2024, an estimated $44.
  • Capital Performance Advisors first reported a position in Redhill Biopharma in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Redhill Biopharma position peaked at $44 in Q3 2024.
  • 11 funds tracked by Wall St. Rank held Redhill Biopharma as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.